Q2 Earnings Estimate for ProKidney Issued By HC Wainwright

ProKidney Corp. (NASDAQ:PROK) – Investment analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of ProKidney in a research report issued on Thursday, March 19th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at ($0.34) EPS.

Other research analysts have also issued reports about the company. Jefferies Financial Group raised ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of ProKidney from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

ProKidney Stock Down 1.0%

NASDAQ:PROK opened at $1.93 on Monday. ProKidney has a 12-month low of $0.46 and a 12-month high of $7.13. The firm has a market capitalization of $580.60 million, a price-to-earnings ratio of -3.71 and a beta of 1.75. The stock’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $2.43.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.00 million.

Institutional Investors Weigh In On ProKidney

Institutional investors have recently made changes to their positions in the company. State Street Corp grew its position in shares of ProKidney by 1.1% in the fourth quarter. State Street Corp now owns 480,345 shares of the company’s stock valued at $1,076,000 after purchasing an additional 5,388 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in ProKidney by 2.0% during the 4th quarter. Squarepoint Ops LLC now owns 351,421 shares of the company’s stock worth $787,000 after purchasing an additional 6,845 shares during the last quarter. Zullo Investment Group Inc. acquired a new stake in ProKidney during the 3rd quarter worth approximately $28,000. Cetera Investment Advisers bought a new stake in ProKidney in the 4th quarter valued at $28,000. Finally, ExodusPoint Capital Management LP boosted its stake in ProKidney by 22.8% in the 4th quarter. ExodusPoint Capital Management LP now owns 128,853 shares of the company’s stock valued at $289,000 after purchasing an additional 23,924 shares during the period. Institutional investors own 51.59% of the company’s stock.

Trending Headlines about ProKidney

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: Jefferies upgraded ProKidney, providing an immediate bullish catalyst from a well-known bank that can attract buying interest and coverage. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintains a $12 price target while publishing quarter-by-quarter EPS forecasts (Q1–Q4 2026 and multi‑year estimates). The continued Buy stance and a high target provide a longer-term bullish narrative for investors focused on upside potential. Read More.
• Neutral Sentiment: Market consensus across eight covering firms is a “Moderate Buy” (mixed mix of buys, holds and sells). That consensus supports modest positive sentiment but shows notable analyst divergence (including two sell ratings). Read More.
• Negative Sentiment: HC Wainwright lowered several future EPS forecasts (FY2026–FY2029) in its update, trimming near- and medium‑term profitability expectations — a headwind for valuation and nearer-term sentiment despite the maintained Buy rating. Read More.
• Negative Sentiment: Wall Street Zen lowered its rating on PROK, which adds to negative headline risk and may pressure short-term flows from sentiment-driven investors. Read More.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.